Skip to main content
Revance Therapeutics, Inc. (RVNC)
Feb 6, 2025 = RVNC was delisted (reason: acquired by Crown Laboratories)
3.650
0.00 (0.00%)
Inactive · Last trade price on Feb 6, 2025

Revance Therapeutics Revenue

Revance Therapeutics had revenue of $59.88M in the quarter ending September 30, 2024, with 10.66% growth. This brings the company's revenue in the last twelve months to $256.95M, up 25.82% year-over-year. In the year 2023, Revance Therapeutics had annual revenue of $234.04M with 76.55% growth.

Revenue (ttm)
$256.95M
Revenue Growth
+25.82%
P/S Ratio
1.37
Revenue / Employee
$430,394
Employees
597
Market Cap
383.05M

Revenue Chart

History

Fiscal Year End Revenue Change Growth
Dec 31, 2023234.04M101.48M76.55%
Dec 31, 2022132.57M54.77M70.40%
Dec 31, 202177.80M62.47M407.65%
Dec 31, 202015.33M14.91M3,610.65%
Dec 31, 2019413.00K-3.32M-88.92%
Dec 31, 2018 Pro Pro Pro
Dec 31, 2017 Pro Pro Pro
Dec 31, 2016 Pro Pro Pro
Dec 31, 2015 Pro Pro Pro
Dec 31, 2014 Pro Pro Pro
Sources: Historical revenue is based on company filings submitted to the U.S. Securities and Exchange Commission (SEC). The most recent revenue numbers may be taken from company press releases.

Revenue Definition

Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.

Full Definition

RVNC News

More News